Role of Rosuvastatin in Treating Diabetes Mellitus, Heart Fa | 93746

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Role of Rosuvastatin in Treating Diabetes Mellitus, Heart Failure and Hyper Cholesterolemia

Author(s): Tanishq Kumar* and Benumadhab Ghosh


Rosuvastatin is another age HMG-CoA reductase inhibitor exhibiting interesting therapeutic and pharmacodynamics characteristics. It consists of a limited extra hepatic tissue perfusion, a low potential for CYP3A4 connections, and a significant LDL-C lowering limit, and hence has undeniable advantages. In this review article, we explore the pharmacological aspects of rosuvastatin, highlighting its reliability. We also examine the significant medical investigations involving hereditary hypercholesterolemia and its association to various statins. Ultimately, we will address its role in clinical treatment. Coronary illness (CHD) is the main source of death around the world. The viability and security of statins in essential and optional avoidance of CHD is affirmed in a few enormous investigations. The most notable statin to hit the market is rosuvastatin. It is observed that 5-20 mg/day is effective and safe in lowering LDL in different ages of individuals with hypercholesterolemia, even in the elderly. Rosuvastatin also has relaxing and anti-atherosclerotic properties, such as lowering arterial thickness and subsequently deteriorating plaque region. Several articles have determined approximately 92 percent of individuals having type 2 diabetes who do not have a heart disease are at risk of developing a dyslipidemic profile. According to current cardiovascular risk guidelines, people diagnosed with DM Type-II should be regarded under high risk of CVD and must get lipid lowering medication to reduce LDL to less than 2.5 millimol/L. Statins have revolutionized CVD management since their introduction. Rosuvastatin is the most recent statin to be introduced.

Share this article